Mechanism-informed combination therapy and dynamic risk stratification in lupus nephritis: toward durable renal protection.

Lupus nephritis remains a major determinant of chronic kidney disease, kidney failure, renal flare, and treatment-related damage in systemic lupus erythematosus. Conventional induction and maintenance therapy with glucocorticoids plus mycophenolate mofetil or cyclophosphamide remains an essential backbone, but it is insufficient for some patients with high-risk clinicopathological features, slow early response, or recurrent flares. The therapeutic landscape is shifting from delayed rescue toward earlier, mechanism-informed combination therapy in selected patients. Belimumab, calcineurin inhibitors, and obinutuzumab should not be interpreted as interchangeable escalation steps. Belimumab is most defensible for persistent immune activity, relapse-prone disease, and glucocorticoid-sparing goals. Calcineurin inhibitors are most useful when proteinuria and podocyte or filtration-barrier injury predominate in patients with preserved or relatively preserved kidney function. Obinutuzumab introduces a deeper B-cell-depleting strategy supported by phase III evidence, although questions remain regarding long-term safety, sequencing, retreatment, cost, and implementation. This review proposes a pragmatic framework integrating baseline clinical and histological risk, early proteinuria and estimated glomerular filtration rate trajectories, urinary sediment, serological activity, selected repeat biopsy, and emerging biomarkers. The objective is durable renal protection through fewer flares, preserved kidney function, minimized glucocorticoid exposure, reduced treatment-related harm, and feasible individualized nephroprotection.